2024
Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine
Machavariani E, Dumchev K, Pykalo I, Filippovych M, Ivasiy R, Esserman D, Madden L, Bromberg D, Haddad M, Morozova O, Ahmad B, Gómez D, Farnum S, Dvoriak S, Altice F. Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine. Contemporary Clinical Trials 2024, 146: 107690. PMID: 39265780, PMCID: PMC11531372, DOI: 10.1016/j.cct.2024.107690.Peer-Reviewed Original ResearchPrimary care centersQuality health indicatorsNon-communicable diseasesSpecialty treatment centersOpioid agonist therapyImplementation of integrated carePay-for-performance incentivesPrimary care clinicsPrimary care settingSelf-reported prevalencePay-for-performancePrevalence of medical comorbiditiesParticipants self-reportedEffective evidence-based treatmentsHealth of PWIDEvidence-based treatmentsIntegrated careCare clinicsImplementation outcomesImplementation trialCare settingsElectronic chart reviewHigh-burden countriesSpecialty servicesHIV prevalenceIntegrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge
Bromberg D, Machavariani E, Madden L, Dumchev K, LaMonaca K, Earnshaw V, Pykalo I, Filippovych M, Haddad M, Dvoriak S, Altice F. Integrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge. Journal Of The International AIDS Society 2024, 27: e26202. PMID: 38379179, PMCID: PMC10879646, DOI: 10.1002/jia2.26202.Peer-Reviewed Original ResearchConceptsPrimary care clinicsStigma reduction interventionsOpioid agonist therapyClinicians' attitudesStigma constructsHIV preventionReduction interventionsEvidence-based HIV preventionCluster randomized controlled trialEvidence-based carePrimary care settingIntegrated care sitesDirect providersRandomized controlled trialsProvider stigmaCare clinicsCare sitesHIV careCare settingsHealth outcomesClinical staffSubstance use disordersLinear mixed-effects modelsTreatment continuumImprove attitudes
2021
Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study
Meteliuk A, Galvez S, Fomenko T, Kalandiia H, Iaryi V, Farnum SO, Islam Z, Altice FL, Madden LM. Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study. Journal Of Substance Use And Addiction Treatment 2021, 134: 108619. PMID: 34579978, DOI: 10.1016/j.jsat.2021.108619.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyPrimary care clinicsPrimary care settingOAT coverageAgonist therapyStable patientsCare clinicsSubstance useCare settingsNegative urine drug testsSpecialty addictions treatmentUrine drug testsSymptom Identification ScaleMental health symptomsAddiction treatment clinicsHIV transmissionPrimary careTreatment clinicsOAT patientsBASIS-24PatientsHealth symptomsEmotional labilityAddiction treatmentPilot study
2016
The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and ways Forward to Promote retention in treatment
Bojko MJ, Mazhnaya A, Marcus R, Makarenko I, Islam Z, Filippovych S, Dvoriak S, Altice FL. The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and ways Forward to Promote retention in treatment. Journal Of Substance Use And Addiction Treatment 2016, 66: 37-47. PMID: 27211995, PMCID: PMC4919997, DOI: 10.1016/j.jsat.2016.03.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidDelivery of Health CareFemaleFocus GroupsGrounded TheoryHumansMaleOpiate Substitution TreatmentOpioid-Related DisordersPatient Acceptance of Health CarePractice Guidelines as TopicPractice Patterns, Physicians'Quality ImprovementSubstance Abuse, IntravenousUkraineConceptsOpioid agonist therapyOAT retentionAgonist therapyTreatment goalsAdditional patient educationRealistic treatment goalsPrimary care settingQuality improvement interventionsCommunity-level barriersPatient educationOpioid addictionCare settingsTreatment retentionMultilevel barriersTreatment settingsImprovement interventionsPWIDMedical staffTherapyTreatmentCommunity awarenessDelivery barriersExperiences of PWIDHigh attritionFocus groups
2009
Comparison of Tuberculin Skin Testing Reactivity in Opioid-Dependent Patients Seeking Treatment with Methadone versus Buprenorphine: Policy Implications for Tuberculosis Screening
Schwarz RK, Bruce RD, Ball SA, Herme M, Altice FL. Comparison of Tuberculin Skin Testing Reactivity in Opioid-Dependent Patients Seeking Treatment with Methadone versus Buprenorphine: Policy Implications for Tuberculosis Screening. The American Journal Of Drug And Alcohol Abuse 2009, 35: 439-444. PMID: 20014914, DOI: 10.3109/00952990903447741.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentTuberculin skin testingBuprenorphine maintenance treatmentOpioid-dependent patientsTST positivityMaintenance treatmentBMT programRetrospective cohort studyPrimary care settingSimilar high prevalenceCross-sectional analysisEthnic health disparitiesBMT patientsBMT settingCohort studyTuberculosis infectionSkin testingTuberculosis screeningTST resultsMMT programPatient populationPrimary careHigh prevalenceCare settingsPatients
2006
Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
Khalsa J, Vocci F, Altice F, Fiellin D, Miller V. Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment. Clinical Infectious Diseases 2006, 43: s169-s172. PMID: 17109302, DOI: 10.1086/508179.BooksMeSH KeywordsAntiretroviral Therapy, Highly ActiveBuprenorphineDelivery of Health Care, IntegratedFemaleFollow-Up StudiesHealth Services ResearchHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersPrimary Health CarePrimary PreventionRisk AssessmentSurvival AnalysisTreatment OutcomeUnited StatesConceptsHuman immunodeficiency virusDrug abuseCare settingsTreatment of HIVHIV primary care settingPrimary HIV care settingsMental Health Services AdministrationHIV primary careProvision of buprenorphineActive antiretroviral therapyHIV care settingsPrimary care settingCollaborative HIV ResearchHealth Services AdministrationAddiction/dependenceAntiretroviral therapyHIV infectionImmunodeficiency syndromeImmunodeficiency virusPrimary careSuccessful treatmentDrug abusersHIV researchDisease controlSubstance abuse